Glucagon-like peptides 1 and 2 in health and disease: a review

Peptides. 2013 Jun;44:75-86. doi: 10.1016/j.peptides.2013.01.014. Epub 2013 Mar 20.

Abstract

The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as 'incretin' hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent.

Publication types

  • Review

MeSH terms

  • Animals
  • Blood Glucose
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy
  • Gastric Emptying
  • Glucagon-Like Peptide 1 / physiology*
  • Glucagon-Like Peptide 1 / therapeutic use
  • Glucagon-Like Peptide 2 / physiology*
  • Glucagon-Like Peptide 2 / therapeutic use
  • Humans
  • Incretins / metabolism
  • Pancreas / metabolism
  • Pancreas / pathology
  • Postprandial Period
  • Receptors, Glucagon / metabolism

Substances

  • Blood Glucose
  • Glucagon-Like Peptide 2
  • Incretins
  • Receptors, Glucagon
  • Glucagon-Like Peptide 1